P Xu1, G-D Sun, Z-Z Li. 1. Department of Spinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China. lizhizhonghy@163.com.
Abstract
OBJECTIVE: Subsequent to a global outbreak of the Middle East Respiratory Syndrome (MERS) in 2012, a novel human coronavirus, known as Corona Virus Disease 2019 (COVID-19) has caused a major disease outbreak. The aim of this study was to perform a systematic review to compare epidemiological, clinical, and laboratory features of COVID-19 and MERS-COV populations. MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials database to identify potential studies that have reported COVID-19 or MERS-COV disease. Epidemiology, clinical, and laboratory outcomes, intensive care unit (ICU) admission rates, discharge rates, and fatality rates were evaluated using Graph-Pad Prism software. RESULTS: A total of forty-two studies were included in our research, involving in 4,720 patients (COVID-19 = 2,012, MERS-COV = 2,708). The present study revealed that main clinical manifestations of both COVID-19 and MERS-COV populations are fever, cough and generalized weakness or myalgia, and Acute Respiratory Distress Syndrome (ARDS) is the main complication. The COVID-19 population has a lower rate of ICU admissions, discharges, fatalities, and shorter incubation periods than those of MERS-COV population. CONCLUSIONS: The main clinical features of both COVID-19 and MERS-COV populations are fever, cough and generalized weakness or myalgia. ARDS is the main complication of both populations. COVID-19 cases have a shorter incubation period and lower rate of ICU admissions, discharges and fatalities compared to MRES-COV population.
OBJECTIVE: Subsequent to a global outbreak of the Middle East Respiratory Syndrome (MERS) in 2012, a novel human coronavirus, known as Corona Virus Disease 2019 (COVID-19) has caused a major disease outbreak. The aim of this study was to perform a systematic review to compare epidemiological, clinical, and laboratory features of COVID-19 and MERS-COV populations. MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials database to identify potential studies that have reported COVID-19 or MERS-COV disease. Epidemiology, clinical, and laboratory outcomes, intensive care unit (ICU) admission rates, discharge rates, and fatality rates were evaluated using Graph-Pad Prism software. RESULTS: A total of forty-two studies were included in our research, involving in 4,720 patients (COVID-19 = 2,012, MERS-COV = 2,708). The present study revealed that main clinical manifestations of both COVID-19 and MERS-COV populations are fever, cough and generalized weakness or myalgia, and Acute Respiratory Distress Syndrome (ARDS) is the main complication. The COVID-19 population has a lower rate of ICU admissions, discharges, fatalities, and shorter incubation periods than those of MERS-COV population. CONCLUSIONS: The main clinical features of both COVID-19 and MERS-COV populations are fever, cough and generalized weakness or myalgia. ARDS is the main complication of both populations. COVID-19 cases have a shorter incubation period and lower rate of ICU admissions, discharges and fatalities compared to MRES-COV population.
Authors: Gowhar Meraj; Majid Farooq; Suraj Kumar Singh; Shakil A Romshoo; M S Nathawat; Shruti Kanga Journal: Environ Dev Sustain Date: 2020-07-10 Impact factor: 3.219
Authors: Qasim Bukhari; Joseph M Massaro; Ralph B D'Agostino; Sheraz Khan Journal: Int J Environ Res Public Health Date: 2020-07-27 Impact factor: 3.390
Authors: Joel D Trinity; Jesse C Craig; Caitlin C Fermoyle; Alec I McKenzie; Matthew T Lewis; Soung Hun Park; Matthew T Rondina; Russell S Richardson Journal: J Appl Physiol (1985) Date: 2021-05-18
Authors: Nathaniel P Disser; Andrea J De Micheli; Martin M Schonk; Maxwell A Konnaris; Alexander N Piacentini; Daniel L Edon; Brett G Toresdahl; Scott A Rodeo; Ellen K Casey; Christopher L Mendias Journal: J Bone Joint Surg Am Date: 2020-07-15 Impact factor: 6.558
Authors: Jorge L Alvarado-Socarras; Andrea Liliana Vesga-Varela; Doris Cristina Quintero-Lesmes; Marcela M Fama-Pereira; Norma C Serrano-Diaz; Mauricio Vasco; Virgil Carballo-Zarate; Lysien I Zambrano; Alberto Paniz-Mondolfi; Alfonso J Rodriguez-Morales Journal: Vaccines (Basel) Date: 2021-03-19